- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00043368
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
A Continuation Study Of PF-3512676 (CPG 7909) Injection In Patients With Metastatic Or Recurrent Malignancies Who Have Stable Disease Or Who Have Responded To Pf-3512676 Injection Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Koeln, Germany, 50931
- Pfizer Investigational Site
-
-
-
-
California
-
Berkely, California, United States, 94704
- Pfizer Investigational Site
-
Gilroy, California, United States, 95020
- Pfizer Investigational Site
-
Hollister, California, United States, 95023
- Pfizer Investigational Site
-
Los Angeles, California, United States, 90057
- Pfizer Investigational Site
-
Los Angeles, California, United States, 91342
- Pfizer Investigational Site
-
Palm Springs, California, United States, 92262
- Pfizer Investigational Site
-
Stanford, California, United States, 94305
- Pfizer Investigational Site
-
-
Connecticut
-
New Haven, Connecticut, United States, 06504
- Pfizer Investigational Site
-
-
Florida
-
Bonita Springs, Florida, United States, 34135
- Pfizer Investigational Site
-
Bradenton, Florida, United States, 34209
- Pfizer Investigational Site
-
Cape Coral, Florida, United States, 33990
- Pfizer Investigational Site
-
Fort Myers, Florida, United States, 33901
- Pfizer Investigational Site
-
Fort Myers, Florida, United States
- Pfizer Investigational Site
-
Naples, Florida, United States, 34102
- Pfizer Investigational Site
-
Plantation, Florida, United States, 33324
- Pfizer Investigational Site
-
Port Charlotte, Florida, United States, 33980
- Pfizer Investigational Site
-
Sarasota, Florida, United States, 34232
- Pfizer Investigational Site
-
Venice, Florida, United States, 34285
- Pfizer Investigational Site
-
Venice, Florida, United States, 34292
- Pfizer Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Pfizer Investigational Site
-
Chicago, Illinois, United States, 60611-3124
- Pfizer Investigational Site
-
-
Indiana
-
Vincennes, Indiana, United States, 47591
- Pfizer Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Pfizer Investigational Site
-
-
Mississippi
-
Olive Branch, Mississippi, United States, 38654
- Pfizer Investigational Site
-
Oxford, Mississippi, United States, 38655
- Pfizer Investigational Site
-
-
New Jersey
-
Livingston, New Jersey, United States, 07039
- Pfizer Investigational Site
-
-
North Carolina
-
Asheville, North Carolina, United States, 28801
- Pfizer Investigational Site
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Pfizer Investigational Site
-
-
Tennessee
-
Collierville, Tennessee, United States, 38107
- Pfizer Investigational Site
-
Memphis, Tennessee, United States, 38104
- Pfizer Investigational Site
-
Memphis, Tennessee, United States, 38017
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Immediate (within 4 weeks) prior completion of a clinical trial of PF-3512676 Injection alone or in combination with other anti-neoplastic treatment for malignancy.
Exclusion Criteria:
The patient has received any anti-neoplastic therapy since completing a prior trial with PF-3512676 Injection, or has participated in another clinical trial following participation in a trial with PF-3512676 Injection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
Patients will be treated with the same dosing regimen and schedule of PF-3512676 Injection with which they were treated at the end of the previous PF-3512676 Injection trial.
Any proposed changes to their schedule/regimen will be at the discretion of the treating physician, following consultation with Coley.
|
PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse Events and DLTs will be evaluated by the Investigator and summarized.
Time Frame: indeterminate
|
indeterminate
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
No formal statistical analysis of this study will be conducted. All clinical data may be summarized and included in data listings.
Time Frame: indeterminate
|
indeterminate
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Respiratory Tract Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lung Diseases
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Kidney Neoplasms
- Lung Neoplasms
- Lymphoma
- Carcinoma, Renal Cell
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma
- Lymphoma, T-Cell
Other Study ID Numbers
- C016
- CO16, A8501015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
Clinical Trials on PF-3512676
-
Ronald LevyPfizerCompletedLymphoma | Lymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Follicular / Indolent B-CellUnited States
-
Ronald LevyAmerican Society of Clinical Oncology; Lymphoma Research FoundationCompletedMycosis Fungoides | Non-Hodgkin LymphomaUnited States
-
PfizerWithdrawn
-
PfizerCompletedCarcinoma, Metastatic BreastUnited States
-
PfizerCompletedCarcinoma, Non-Small-Cell LungUnited States
-
PfizerTerminatedCarcinoma, Non-Small Cell LungUnited States, Germany, Italy
-
PfizerTerminatedCarcinoma, Non-Small-Cell LungAustralia, United States, Hungary, Germany, Italy, Korea, Republic of, Spain, Sweden, Mexico, South Africa, Taiwan, Belgium, Canada, China, Cyprus, Czech Republic, France, Greece, Hong Kong, India, Israel, Netherlands, Poland, Portugal, Switzerlan... and more
-
PfizerTerminatedCarcinoma, Non-Small-Cell LungUnited States, Canada, Belgium, Italy, Spain, United Kingdom, Korea, Republic of, Netherlands, Poland, Portugal, Turkey, Taiwan, Germany, Hungary, Brazil, Hong Kong, Singapore, South Africa, China, Austria, Czech Republic, India, Is... and more
-
Milestone Pharmaceuticals Inc.RecruitingParoxysmal Supraventricular TachycardiaUnited States